Type 2 diabetes prevention

Interleukin-1 beta inhibition with canakinumab does not prevent the development of type 2 diabetes, a secondary analysis of data from CANTOS shows.

Findings from the CARDIA study support the contention that modifiable risk factors account for the excess type 2 diabetes risk in Black versus White people during middle-age.

The QDiabetes risk assessment tool for type 2 diabetes has been updated with an expanded range of risk factors and additional models that incorporate blood glucose tests.

A partnership between primary care and commercial weight management providers could help reduce the risk for type 2 diabetes among patients with hyperglycemia, UK study findings show.

People with higher levels of linoleic acid biomarkers have a reduced risk for type 2 diabetes than those with lower levels, whereas its metabolite arachidonic acid is not significantly associated with type 2 diabetes risk, study results suggest.

Less than one-third of patients with type 2 diabetes and cardiovascular disease are receiving optimal care for secondary prevention of cardiovascular events, suggests an analysis of data from the TECOS trial.

Data from the first 4 years of implementation of the US National Diabetes Prevention Program show promising results, with the more engaged patients achieving the best outcomes.

Read the linked commentary from Leonard Bertheau.

Impaired fasting plasma glucose and insulin resistance are associated with an increased risk for developing cognitive dysfunction among postmenopausal women, results of a Danish study suggest.

Liraglutide enhances the positive effects of lifestyle intervention on weight loss and glycemic control in patients with prediabetes, show the 3-year outcomes of the SCALE Obesity and Prediabetes trial.

Simply maintaining weight during adulthood, at a population level, could prevent one in five diabetes cases, report researchers.

Screening measures for prediabetes do not accurately identify people at risk for developing diabetes, so preventive interventions will have only a small impact, say the authors of a meta-analysis published in The BMJ.

Long-term treatment with low-dose aspirin does not reduce the risk for cardiovascular events in Japanese patients with type 2 diabetes without pre-existing atherosclerotic disease, suggest 10-year results of the JPAD trial.